Zynerba Pharmaceuticals Inc (ZYNE) Holdings Boosted by Virtu Financial LLC

Two Sigma Investments LP purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $120,000.

Zynerba Pharmaceuticals logoVirtu Financial LLC raised its stake in Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 66.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,384 shares of the company’s stock after purchasing an additional 8,970 shares during the period. Virtu Financial LLC owned 0.11% of Zynerba Pharmaceuticals worth $121,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in Zynerba Pharmaceuticals in the third quarter valued at approximately $177,000. Jane Street Group LLC grew its position in shares of Zynerba Pharmaceuticals by 44.6% during the third quarter. Jane Street Group LLC now owns 35,555 shares of the company’s stock worth $290,000 after acquiring an additional 10,967 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $120,000. Campbell Capital Management Inc. purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $510,000. Finally, Deutsche Bank AG grew its position in shares of Zynerba Pharmaceuticals by 17,314.3% during the fourth quarter. Deutsche Bank AG now owns 279,500 shares of the company’s stock worth $830,000 after acquiring an additional 277,895 shares during the last quarter. Institutional investors own 12.95% of the company’s stock.

NASDAQ:ZYNE opened at $12.52 on Wednesday. Zynerba Pharmaceuticals Inc has a 1-year low of $2.75 and a 1-year high of $12.89. The firm has a market capitalization of $231.56 million, a P/E ratio of -4.80 and a beta of 4.93.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.21. The firm had revenue of $0.09 million during the quarter. As a group, equities analysts anticipate that Zynerba Pharmaceuticals Inc will post -2.1 earnings per share for the current year.

A number of brokerages have recently issued reports on ZYNE. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Roth Capital assumed coverage on shares of Zynerba Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $36.00 target price on the stock. Canaccord Genuity assumed coverage on shares of Zynerba Pharmaceuticals in a research report on Monday, April 22nd. They issued a “buy” rating and a $8.09 price objective on the stock. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Friday, March 22nd. Finally, HC Wainwright reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Monday, March 18th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Zynerba Pharmaceuticals has a consensus rating of “Buy” and an average price target of $17.02.

TRADEMARK VIOLATION NOTICE: “Zynerba Pharmaceuticals Inc (ZYNE) Holdings Boosted by Virtu Financial LLC” was first posted by Finance Daily and is the property of of Finance Daily. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.fidaily.com/2019/05/01/zynerba-pharmaceuticals-inc-zyne-holdings-boosted-by-virtu-financial-llc.html.

Zynerba Pharmaceuticals Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.

Recommended Story: Preferred Stock

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Zynerba Pharmaceuticals (ZYNE) Trading Up 6.8%

Two Sigma Investments LP bought a new position in Zynerba Pharmaceuticals during the 4th quarter valued at about $120,000. GSA Capital Partners …

Zynerba Pharmaceuticals logoShares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) were up 6.8% during trading on Monday . The stock traded as high as $11.81 and last traded at $11.74. Approximately 61,154 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 3,139,999 shares. The stock had previously closed at $10.99.

Several analysts have commented on ZYNE shares. ValuEngine cut shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $11.00 price target on shares of Zynerba Pharmaceuticals in a research note on Thursday, March 7th. Canaccord Genuity started coverage on shares of Zynerba Pharmaceuticals in a research note on Monday, April 22nd. They issued a “buy” rating and a $8.09 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a research note on Monday, March 18th. Finally, Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Saturday, January 19th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Zynerba Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $12.27.

The firm has a market capitalization of $231.56 million, a price-to-earnings ratio of -4.43 and a beta of 4.93.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Monday, March 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.21. The business had revenue of $0.09 million during the quarter. Analysts forecast that Zynerba Pharmaceuticals Inc will post -2.1 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in Zynerba Pharmaceuticals during the 4th quarter valued at about $40,000. Two Sigma Investments LP bought a new position in Zynerba Pharmaceuticals during the 4th quarter valued at about $120,000. GSA Capital Partners LLP bought a new position in Zynerba Pharmaceuticals during the 3rd quarter valued at about $177,000. Jane Street Group LLC grew its holdings in Zynerba Pharmaceuticals by 44.6% during the 3rd quarter. Jane Street Group LLC now owns 35,555 shares of the company’s stock valued at $290,000 after purchasing an additional 10,967 shares during the last quarter. Finally, Campbell Capital Management Inc. bought a new position in Zynerba Pharmaceuticals during the 4th quarter valued at about $510,000. Hedge funds and other institutional investors own 12.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zynerba Pharmaceuticals (ZYNE) Trading Up 6.8%” was first posted by Finance Daily and is the sole property of of Finance Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.fidaily.com/2019/04/29/zynerba-pharmaceuticals-zyne-trading-up-6-8.html.

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.

See Also: The Structure of a Futures Contract

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Zynerba Pharmaceuticals Inc (ZYNE) Receives $11.00 Average Target Price from Brokerages

Two Sigma Investments LP purchased a new position in Zynerba Pharmaceuticals in the fourth quarter valued at approximately $120,000. Finally …

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has earned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.00.

A number of equities analysts have recently weighed in on ZYNE shares. HC Wainwright restated a “buy” rating on shares of Zynerba Pharmaceuticals in a research note on Monday, March 18th. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $11.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Thursday, March 7th. Canaccord Genuity began coverage on Zynerba Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st.

A number of institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC lifted its stake in Zynerba Pharmaceuticals by 66.9% in the first quarter. Virtu Financial LLC now owns 22,384 shares of the company’s stock valued at $121,000 after purchasing an additional 8,970 shares during the last quarter. Campbell Capital Management Inc. lifted its stake in Zynerba Pharmaceuticals by 5.3% in the first quarter. Campbell Capital Management Inc. now owns 180,787 shares of the company’s stock valued at $980,000 after purchasing an additional 9,100 shares during the last quarter. Deutsche Bank AG lifted its stake in Zynerba Pharmaceuticals by 17,314.3% in the fourth quarter. Deutsche Bank AG now owns 279,500 shares of the company’s stock valued at $830,000 after purchasing an additional 277,895 shares during the last quarter. Two Sigma Investments LP purchased a new position in Zynerba Pharmaceuticals in the fourth quarter valued at approximately $120,000. Finally, BlackRock Inc. lifted its stake in Zynerba Pharmaceuticals by 0.9% in the fourth quarter. BlackRock Inc. now owns 300,949 shares of the company’s stock valued at $893,000 after purchasing an additional 2,594 shares during the last quarter. Institutional investors and hedge funds own 12.86% of the company’s stock.

Shares of NASDAQ ZYNE traded up $1.41 during midday trading on Monday, reaching $9.50. The company’s stock had a trading volume of 4,173,895 shares, compared to its average volume of 1,579,940. Zynerba Pharmaceuticals has a 12-month low of $2.75 and a 12-month high of $12.50. The company has a market capitalization of $170.46 million, a PE ratio of -3.64 and a beta of 4.93.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Monday, March 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.21. The business had revenue of $0.09 million during the quarter. Research analysts expect that Zynerba Pharmaceuticals will post -2.1 earnings per share for the current fiscal year.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.

See Also: Front-End Load

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Vanguard Group Inc. Acquires 125327 Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Vanguard Group Inc. grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% during the third quarter, according to its …

Zynerba Pharmaceuticals logoVanguard Group Inc. grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 651,400 shares of the company’s stock after purchasing an additional 125,327 shares during the quarter. Vanguard Group Inc. owned about 3.69% of Zynerba Pharmaceuticals worth $5,316,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new position in Zynerba Pharmaceuticals in the 3rd quarter worth $612,000. BlackRock Inc. increased its holdings in shares of Zynerba Pharmaceuticals by 25.2% during the 3rd quarter. BlackRock Inc. now owns 298,355 shares of the company’s stock worth $2,435,000 after purchasing an additional 59,998 shares during the period. Engineers Gate Manager LP increased its holdings in shares of Zynerba Pharmaceuticals by 179.8% during the 3rd quarter. Engineers Gate Manager LP now owns 66,270 shares of the company’s stock worth $541,000 after purchasing an additional 42,583 shares during the period. Zeke Capital Advisors LLC bought a new position in shares of Zynerba Pharmaceuticals during the 3rd quarter worth about $193,000. Finally, GSA Capital Partners LLP bought a new position in shares of Zynerba Pharmaceuticals during the 3rd quarter worth about $177,000. Institutional investors and hedge funds own 12.86% of the company’s stock.

Shares of NASDAQ ZYNE traded down $0.07 during trading on Tuesday, reaching $5.65. The company had a trading volume of 460,162 shares, compared to its average volume of 1,087,509. Zynerba Pharmaceuticals Inc has a 52 week low of $2.75 and a 52 week high of $12.50. The company has a market cap of $122.21 million, a PE ratio of -2.16 and a beta of 4.93.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Monday, March 11th. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.21. The company had revenue of $0.09 million during the quarter. As a group, research analysts expect that Zynerba Pharmaceuticals Inc will post -2.1 earnings per share for the current year.

Several research analysts have recently issued reports on ZYNE shares. Cantor Fitzgerald set a $21.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 5th. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Saturday, January 19th. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Finally, HC Wainwright restated a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Monday, March 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Zynerba Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $14.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Modern Readers and is owned by of Modern Readers. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.modernreaders.com/news/2019/03/26/vanguard-group-inc-increases-position-in-zynerba-pharmaceuticals-inc-zyne.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Featured Story: What is the price-to-earnings growth (PEG) ratio?

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

2 Stocks That Are Just Getting Started: Zynerba Pharmaceuticals, Inc. (ZYNE), Ventas, Inc. (VTR)

That day the Seaport Global Securities set price target on the stock to $16. The stock was given Overweight rating by Cantor Fitzgerald in its report …

The shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has been pegged with a rating of Buy by H.C. Wainwright in its latest research note that was published on February 1st, 2018. The research company has also assigned a $23 price target. H.C. Wainwright wasn’t the only research firm that published a report of Zynerba Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. Ladenburg Thalmann advised investors in its research note published on January 29th, 2018, to Buy the ZYNE stock while also putting a $25.50 price target. The stock had earned Buy rating from Seaport Global Securities when it published its report on January 26th, 2018. That day the Seaport Global Securities set price target on the stock to $16. The stock was given Overweight rating by Cantor Fitzgerald in its report released on October 2nd, 2017, the day when the price target on the stock was placed at $17. Piper Jaffray was of a view that ZYNE is Overweight in its latest report on September 29th, 2017. ROTH Capital thinks that ZYNE is worth Buy rating. This was contained in the firm’s report on August 15th, 2017.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $16.30. The price of the stock the last time has raised by 102.55% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 63.60.

The shares of the company added by 15.08% during the trading session on Tuesday, reaching a low of $4.92 while ending the day at $5.57. During the trading session, a total of 3.01 million shares were traded which represents a -327991.71% decline from the average session volume which is 917.05K shares. ZYNE had ended its last session trading at 4.84. Zynerba Pharmaceuticals, Inc. currently has a market cap of $115.63M while its P/E earnings growth sits at 1344.57, with a beta of 4.94. Zynerba Pharmaceuticals, Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 6.90. ZYNE 52-week low price stands at $2.75 while its 52-week high price is $12.50.

The company in its last quarterly report recorded -$0.44 earnings per share which is above the -$0.65 predicted by most analysts. In the second quarter last year, the firm recorded -$0.47 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -6.82%. Zynerba Pharmaceuticals, Inc. has the potential to record -2.72 EPS for the current fiscal year, according to equities analysts.

Investment analysts at RBC Capital Mkts published a research note on November 2nd, 2018 where it informed investors and clients that Ventas, Inc. (NYSE:VTR) is now rated as Sector Perform. Ladenburg Thalmann also rated VTR as Initiated on January 29th, 2018, with its price target of $42 suggesting that VTR could surge by 0.02% from its current share price. Even though the stock has been trading at $61.51/share, analysts expect it to surge higher by -0.70% to reach $61.09/share. It started the day trading at $61.49 and traded between $60.735 and $61.08 throughout the trading session.

A look at its technical shows that VTR’s 50-day SMA is 62.52 while its 200-day SMA stands at 59.08. The stock has a high of $65.70 for the year while the low is $46.55. The company’s P/E ratio currently sits at 64.50, while the P/B ratio is 2.09. At the moment, only of Ventas, Inc. shares were sold short. The company’s average trading volume currently stands at 2.11M shares, which means that the short-interest ratio is just 2.38 days. Over the past seven days, the company moved, with its shift of -3.74%. Looking further, the stock has dropped -2.37% over the past 90 days while it gained 5.57% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more VTR shares, increasing its portfolio by +0.12% during the last quarter. This move now sees The Vanguard Group Inc purchasing 54,824 shares in the last quarter, thus it now holds 44,647,893 shares of VTR, with a total valuation of $2,801,655,286. BlackRock Fund Advisors meanwhile bought more VTR shares in the recently filed quarter, changing its stake to $1,648,670,534 worth of shares. SSgA Funds Management Inc followed the path by increasing its VTR portfolio by +1.50% in the quarter. This means that SSgA Funds Management Inc bought 311,198 shares in the last quarter and now controls 21,000,958 shares of the VTR stock, with the valuation hitting $1,317,810,115.

Similarly, Fidelity Management Research Co decreased its Ventas, Inc. shares by -4.14% during the recently filed quarter. After selling -467,746 shares in the last quarter, the firm now controls 10,841,701 shares of Ventas, Inc. which are valued at $680,316,738. In the same vein, Cohen Steers Capital Management increased its Ventas, Inc. shares by during the most recent reported quarter. The firm bought 8,876,600 shares during the quarter which increased its stakes to 10,509,102 shares and is now valued at $659,446,151. Following these latest developments, around 0.40% of Ventas, Inc. stocks are owned by institutional investors and hedge funds.

Related Posts:

  • No Related Posts